Gilead Sciences secures USFDA okay for Trodelvy for pre-treated HR+/HER2- Metastatic Breast Cancer Ruchika Sharma4 Feb 2023 11:37 AM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
EMA validates marketing authorization application for Trodelvy for Pre-treated HR+/HER2- Metastatic Breast Cancer: Gilead Sciences Ruchika Sharma5 Jan 2023 4:30 PM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Gilead Sciences to acquire all remaining rights to potential first-in-class immunotherapy GS-1811 from Jounce Therapeutics Ruchika Sharma28 Dec 2022 12:30 PM ISTJounce will receive proceeds of $67 million for this transaction, and Gilead will be solely responsible for all further research, development, and...
Gilead Sciences bags USFDA nod for Sunlenca to treat HIV-1 infection Ruchika Sharma23 Dec 2022 4:09 PM ISTLenacapavir is a breakthrough innovation with the potential to be a preferred and versatile foundational long-acting agent due to its therapeutic...
Gilead Sciences Trodelvy under USFDA priority review for adult patients with pretreated metastatic breast cancer Ruchika Sharma14 Oct 2022 2:30 PM ISTTrodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate.
Shilpa Medicare gets USFDA nod for Tenofovir Alafenamide Tablets Ruchika Sharma19 Sept 2022 11:25 AM ISTNew Delhi: Shilpa Medicare has recently announced that the Company has received U.S Food and Drug Administration (USFDA) tentative approval for...
Gilead Sciences' Kite gets European Commission nod for CAR T-cell therapy Tecartus Ruchika Sharma8 Sept 2022 4:00 PM ISTSanta Monica, Calif.: Kite, a Gilead Company has announced that the European Commission (EC) has approved its CAR T-cell therapy Tecartus...
Gilead Sciences bags European Commission nod for HIV drug Sunlenca Ruchika Sharma23 Aug 2022 1:30 PM ISTSunlenca is indicated in the European Union for the treatment of adults with multi-drug resistant HIV infection in combination with other...
Gilead Sciences to acquire MiroBio for Rs 3225 crore Ruchika Sharma9 Aug 2022 11:00 AM ISTThe acquisition will provide Gilead with MiroBio's proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists.
Gilead Sciences drug Trodelvy modestly delays breast cancer progression in late-stage trial Ruchika Sharma6 Jun 2022 4:09 PM ISTWall Street analysts, on average, expect annual sales of the drug will top $2 billion 2026, according to Refinitiv.
Gilead, Dragonfly ink pact to develop natural killer cell engagers in oncology, inflammation Ruchika Sharma5 May 2022 9:15 AM ISTUnder the terms of the agreement, Gilead will make a $300 million upfront payment to Dragonfly.
Gilead Sciences Remdesivir gets USFDA nod for young children Ruchika Sharma26 April 2022 3:06 PM ISTUnder the expanded indication, a three-day Remdesivir treatment regimen is recommended to help prevent hospitalization in non-hospitalized COVID-19...
